Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group (Q47884003)
Jump to navigation
Jump to search
scientific article published in May 1998
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group |
scientific article published in May 1998 |
Statements
1 reference
Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group (English)
1 reference
1 reference
K Tobinai
1 reference
M Narabayashi
1 reference
M Ogura
1 reference
Y Kagami
1 reference
Y Morishima
1 reference
T Ohtsu
1 reference
T Igarashi
1 reference
Y Sasaki
1 reference
T Kinoshita
1 reference
T Murate
1 reference
1 May 1998
1 reference
1 reference
9
1 reference
5
1 reference
527-534
1 reference
Identifiers
1 reference
1 reference